Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days

Transfusion and Apheresis Science

Volumn 54, Issue 2, 2016, Pages 248-252

  Kaplan, Alesia ^a   Lindgren, Bruce ^b   Marschner, Susanne ^c   Aznar, Marivi ^d   Zalba, Saioa ^d   Sánchez, Piva ^d   Ayape, María Luisa ^e   Olavarría, Eduardo ^d   Antelo, Maria Luisa ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Terumo BCT   (United States)

^d Instituto de Investigación Sanitaria de Navarra   (Spain)

^e Banco de Sangre y Tejidos de Navarra   (Spain)

Author keywords

CI24hs; Extended storage; Pathogen reduction technology (PRT); Platelets; Riboflavin

Indexed keywords

RIBOFLAVIN; THROMBOCYTE CONCENTRATE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; APHERESIS DEVICE; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD BUFFY COAT; CONTROLLED STUDY; DEVICE SAFETY; DISPOSABLE EQUIPMENT; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATHOGEN REDUCTION SYSTEM; PATIENT MONITORING; RETROSPECTIVE STUDY; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTE LIFESPAN; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; ULTRAVIOLET RADIATION; ADOLESCENT; AGED; BLOOD SAFETY; BLOOD STORAGE; CHEMISTRY; COMPARATIVE STUDY; DISINFECTION; MIDDLE AGED; PROCEDURES; THROMBOCYTE; TIME FACTOR; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD SAFETY; DISINFECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET TRANSFUSION; RIBOFLAVIN; TIME FACTORS; ULTRAVIOLET RAYS;

EID: 84940874442     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2015.08.004     Document Type: Article

References (32)

1. O'Brien SF, Yi Q-L, Fan W, Scalia V, Fearon MA, Allain J-P Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services. Vox Sang 2012, 103:83-86. 10.1111/j.1423-0410.2012.01584.x.
2. Kleinman S, Chan P, Robillard P Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003, 17:120-162. 10.1053/tmrv.2003.50009.
3. Dumont LJ, Kleinman S, Murphy JR, Lippincott R, Schuyler R, Houghton J, et al. Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion 2010, 50:589-599. 10.1111/j.1537-2995.2009.02460.x.
4. Dodd RY Bacterial contamination and transfusion safety: experience in the United States. Transfus Clin Biol 2003, 10:6-9.
5. Marschner S, Goodrich R Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011, 38:8-18. 10.1159/000324160.
6. Keil SD, Bengrine A, Bowen R, Marschner S, Hovenga N, Rouse L, et al. Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment. Transfusion 2015, 10.1111/trf.13030.
7. Goodrich RP, Gilmour D, Hovenga N, Keil SD A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009, 49:1205-1216. 10.1111/j.1537-2995.2009.02126.x.
8. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004, 44:877-885. 10.1111/j.1537-2995.2004.03355.x.
9. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010, 50:2362-2375. Mirasol Clinical Evaluation Study Group. 10.1111/j.1537-2995.2010.02694.x.
10. Johansson PI, Simonsen AC, Brown PN, Ostrowski SR, Deberdt L, Van Hoydonck P, et al. A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia. Transfusion 2013, 53:2043-2052. 10.1111/trf.12055.
11. Meurou P, Marschner S, Reynaerts I Routine implementation of Mirasol PRT treated platelet concentrates in the Centre Hospitalier Luxemburg. Transfusion 2012, 52:179A.
12. Yañez M, Garcia de Coca A, Medina L, Galvez F, Martin Vaca M, Martinez Alvarez M, et al. Clinical evaluation of platelets treated with riboflavin and UV light in the presence of platelet additive solution in thrombocytopenic patients. Vox Sang 2011, 101:148.
13. Drawz SM, Marschner S, Yañez M, García de Coca A, Feys HB, Deeren D, et al. Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions. Transfusion 2015, 10.1111/trf.13026.
14. Antelo Caamaño M, Zalba Marcos S, Ayape Puyales L, Aranguren Azparren A, Aranburu E, Marschner S Clinical performance of mirasol pathogen reduction technology treated platelets during routine use. Transfusion 2011, 51:58A.
15. Antic A, Stanojkovic Z, Jelic M, Stanojkovic M Clinical efficacy of buffy coat platelets treated with riboflavin and ultraviolet light (Mirasol PRT System). Vox Sang 2011, 101:178.
16. Stanojkovic ZA, Antic AM, Stanojkovic M Clinical performance of buffy coat platelets treated with riboflavin and UV light. Transfusion 2010, 50:66A.
17. Yañez M, Blanco Peris L, Gonzalez Fraile M, Moya San Pedro M, Garcia de Coca A, Cuello R Performance of buffy coat platelets in plasma treated with riboflavin and UV light: in vitro and in vivo evaluation. Transfusion 2009, 49:84A.
18. Cardoso M, Piotrowski D, Przybylska-Baluta Z, Zak A Routine production and clinical use of mirasol platelets and FFP at the regional BTS Warsaw. Vox Sang 2013, 105:283.
19. Letowska M, Poglod R, Lachert E, Antoniewicz-Papis J, Rosiek A Clinical experience of the Warsaw Institute of Hematology and Transfusion Medicine with platelet concentrates treated in the Mirasol PRT System. Vox Sang 2011, 101:182.
20. Piotrowski D, Przybylska-Baluta Z, Leleno M, Uszynska A, Cardoso M Transfusion experience with blood components treated with the Mirasol-PRT system in the regional BTS Warsaw. Vox Sang 2011, 101:188.
21. Letowska M, Przybylska-Baluta Z, Piotrowski D, Rzymkiewicz L, Lachert E, Cardoso M Four-year hemovigilance survey of mirasol-treated blood components in the Warsaw region. Transfusion 2014, 54:98A.
22. Cohn CS, Stubbs J, Schwartz J, Francis R, Goss C, Cushing M, et al. A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion 2014, 54:1927-1934. 10.1111/trf.12597.
23. Picker SM, Tauszig ME, Gathof BS Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution. Transfusion 2012, 52:510-516. 10.1111/j.1537-2995.2011.03323.x.
24. Johnson L, Winter KM, Reid S, Hartkopf-Theis T, Marschner S, Goodrich RP, et al. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 2011, 101:208-214. 10.1111/j.1423-0410.2011.01477.x.
25. Ostrowski SR, Bochsen L, Windeløv NA, Salado-Jimena JA, Reynaerts I, Goodrich RP, et al. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2011, 51:344-356. 10.1111/j.1537-2995.2010.02821.x.
26. Vanlandingham DL, Keil SD, Horne KM, Pyles R, Goodrich RP, Higgs S Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013, 53:284-290. 10.1111/j.1537-2995.2012.03717.x.
27. Tobian AAR, Fuller AK, Uglik K, Tisch DJ, Borge PD, Benjamin RJ, et al. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME). Transfusion 2014, 54:1523-1529. quiz 1522. 10.1111/trf.12498.
28. Schlenke P Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014, 41:309-325. 10.1159/000365646.
29. Fast LD, DiLeone G, Marschner S Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion 2011, 51:1397-1404. 10.1111/j.1537-2995.2010.02984.x.
30. Marschner S, Fast LD, Baldwin WM, Slichter SJ, Goodrich RP White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010, 50:2489-2498. 10.1111/j.1537-2995.2010.02714.x.
31. MacLennan S, Harding K, Llewelyn C, Choo L, Bakrania L, Massey E, et al. A randomized noninferiority crossover trial of corrected count increments and bleeding in thrombocytopenic hematology patients receiving 2- to 5- versus 6- or 7-day-stored platelets. Transfusion 2015, 10.1111/trf.13038.
32. Kryzaukatie L, Marschner S, Deberdt L, Rouse L, Goodrich R Mirasol PRT treated platelet products in autologous stem cell transplant patients. Transfusion 2011, 51:37A.